Skip to main content
SpringerLink
Log in

Therapy of Allergic and Irritant Contact Dermatitis

  • Living reference work entry
  • First Online:
Contact Dermatitis

  • 110 Accesses

Abstract

The treatment of and rehabilitation methods in contact dermatitis and the evidence supporting them are presented, following the “rule of the four Rs”: recognize (the causative allergic/irritant agent), remove (the irritant/allergen), reduce inflammation, and restore the skin barrier. Avoidance of the inducing allergen(s) and/or irritant(s) is the most important aspect in the management of contact dermatitis, and the different measures are reviewed. The principles of basic topical therapy and the treatment modalities – topical corticosteroids, topical calcineurin inhibitors, retinoids, phototherapy, X-ray therapy, and systemic corticosteroids and immunosuppressive agents – are described. Their effects on the skin barrier function, as well as those of moisturizers and other factors influencing barrier recovery, are examined separately.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Nielsen NH, Linneberg A, Menne T et al (2001) Persistence of contact allergy among Danish adults: an 8-year follow-up study. Contact Derm 45:350–353

    CAS  PubMed  Google Scholar 

  2. Mastrolonardo M, Lopalco PL, Diaferio A (2002) Topical immunotherapy with contact sensitizers: a model to study the natural history of delayed hypersensitivity. Contact Derm 47:210–214

    CAS  PubMed  Google Scholar 

  3. Gupta G, Forsyth A (1999) Allergic contact reactions to colophony presenting as oral disease. Contact Derm 40:332–333

    CAS  PubMed  Google Scholar 

  4. Watson ES (1986) Toxicodendron hyposensitization programs. Clin Dermatol 4:160–170

    CAS  PubMed  Google Scholar 

  5. Lofgren SM, Warshaw EM (2006) Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 17:165–181

    PubMed  Google Scholar 

  6. Sharma AD (2007) Relationship between nickel allergy and diet. Indian J Dermatol Venereol Leprol 73:307–312

    PubMed  Google Scholar 

  7. Mislankar M, Zirwas MJ (2013) Low-nickel diet scoring system for systemic nickel allergy. Dermatitis 24(4):190–195

    CAS  PubMed  Google Scholar 

  8. Kaaber K, Menne T, Veien NK et al (1987) Some adverse effects of disulfiram in the treatment of nickel-allergic patients. Derm Beruf Umwelt 35:209–211

    CAS  PubMed  Google Scholar 

  9. Diepgen T, Elsner P, Schliemann S et al (2009) Management von handekzemen leitlinie ICD-10-ziffer: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges 7:s1–s16

    PubMed  Google Scholar 

  10. van Coevorden AM, Coenraads PJ, Svensson A et al (2004) Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol 151:446–451

    PubMed  Google Scholar 

  11. Sajjachareonpong P, Cahill J, Keegel T et al (2004) Persistent post-occupational dermatitis. Contact Derm 51:278–283

    PubMed  Google Scholar 

  12. Wall LM, Gebauer KA (1991) A follow-up study of occupational skin disease in Western Australia. Contact Derm 24:241–243

    CAS  PubMed  Google Scholar 

  13. De Paepe K, Hachem JP, Vanpee E et al (2001) Beneficial effects of a skin tolerance-tested moisturizing cream on the barrier function in experimentally-elicited irritant and allergic contact dermatitis. Contact Derm 44:337–343

    PubMed  Google Scholar 

  14. Ramsing DW, Agner T (1997) Preventive and therapeutic effects of a moisturizer. An experimental study of human skin. Acta Derm Venereol 77:335–337

    CAS  PubMed  Google Scholar 

  15. Loden M (2005) The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol 19:672–688. quiz 686–687

    CAS  PubMed  Google Scholar 

  16. Akhavan A, Cohen SR (2003) The relationship between atopic dermatitis and contact dermatitis. Clin Dermatol 21:158–162

    PubMed  Google Scholar 

  17. Folster-Holst R, Latussek E (2007) Synthetic tannins in dermatology–a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24:296–301

    PubMed  Google Scholar 

  18. Nilsson E, Henning C, Hjorleifsson ML (1986) Density of the microflora in hand eczema before and after topical treatment with a potent corticosteroid. J Am Acad Dermatol 15:192–197

    CAS  PubMed  Google Scholar 

  19. Wollina U (2008) Pompholyx: what’s new? Expert Opin Investig Drugs 17:897–904

    CAS  PubMed  Google Scholar 

  20. Walling HW, Swick BL (2011) Treatment options for hyperhidrosis. Am J Clin Dermatol 12(5):285–295

    PubMed  Google Scholar 

  21. Frosch PJ, Schulze-Dirks A (1989) Contact allergy caused by polidocanol. Hautarzt 40:146–14943

    CAS  PubMed  Google Scholar 

  22. Uter W, Geier J, Fuchs T (2000) Contact allergy to polidocanol, 1992 to 1999. J Allergy Clin Immunol 106:1203–1204

    CAS  PubMed  Google Scholar 

  23. van den Bogaard EH et al (2013) Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 123(2):917–927

    PubMed  PubMed Central  Google Scholar 

  24. Veenhuis RT, van Horssen J, Bos RP et al (2002) Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res 294:168–171

    CAS  PubMed  Google Scholar 

  25. Elsner P, Agner T (2020) Hand eczema: treatment. J Eur Acad Dermatol Venereol: JEADV 34(Suppl 1):13–21

    PubMed  Google Scholar 

  26. Levin C, Zhai H, Bashir S et al (2001) Efficacy of corticosteroids in acute experimental irritant contact dermatitis? Skin Res Technol 7:214–218

    CAS  PubMed  Google Scholar 

  27. van der Valk PG, Maibach HI (1989) Do topical corticosteroids modulate skin irritation in human beings? Assessment by transepidermal water loss and visual scoring. J Am Acad Dermatol 21:519–522

    PubMed  Google Scholar 

  28. Kucharekova M, Hornix M, Ashikaga T et al (2003) The effect of the PDE-4 inhibitor (cipamfylline) in two human models of irritant contact dermatitis. Arch Dermatol Res 295:29–32

    CAS  PubMed  Google Scholar 

  29. Ramsing DW, Agner T (1995) Efficacy of topical corticosteroids on irritant skin reactions. Contact Derm 32:293–297

    CAS  PubMed  Google Scholar 

  30. Luger T, Elsner P, Kerscher M et al (2009) Topische Dermatotherapie mit Glukokortikoiden – therapeutischer Index. ICD 10: L20. Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG). Düsseldorf. Retrieved 9 July 2009 from http://www.uni-duesseldorf.de/AWMF/ll/013-034.htm

  31. Luger T, Loske KD, Elsner P et al (2004) Topical skin therapy with glucocorticoids – therapeutic index. J Dtsch Dermatol Ges 2:629–634

    PubMed  Google Scholar 

  32. Wollenberg A, Bieber T (2009) Proactive therapy of atopic dermatitis–an emerging concept. Allergy 64(2):276–278

    CAS  PubMed  Google Scholar 

  33. Wollenberg A et al (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 32(5):657–682

    CAS  PubMed  Google Scholar 

  34. Wollenberg A, Ehmann LM (2012) Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 24(3):253–260

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Schmitt J et al (2011) Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 164(2):415–428

    CAS  PubMed  Google Scholar 

  36. Wollenberg A et al (2009) Proactive therapy of atopic eczema–an evidence-based concept with a behavioral background. Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol: JDDG 7(2):117–121

    Google Scholar 

  37. Veien NK, Olholm Larsen P, Thestrup-Pedersen K et al (1999) Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 140:882–886

    CAS  PubMed  Google Scholar 

  38. Hachem JP, De Paepe K, Vanpee E et al (2001) Combination therapy improves the recovery of the skin barrier function: an experimental model using a contact allergy patch test combined with TEWL measurements. Dermatology 202:314–319

    CAS  PubMed  Google Scholar 

  39. Isaksson M (2004) Corticosteroids. Dermatol Ther 17:314–320

    PubMed  Google Scholar 

  40. Wilkinson SM, Cartwright PH, English JS (1991) Hydrocortisone: an important cutaneous allergen. Lancet 337:761–762

    CAS  PubMed  Google Scholar 

  41. Uter W, de Padua CM, Pfahlberg A et al (2009) Contact allergy to topical corticosteroids–results from the IVDK and epidemiological risk assessment. J Dtsch Dermatol Ges 7(34–41):34–42

    PubMed  Google Scholar 

  42. Isaksson M, Bruze M (2001) Repetitive usage testing with budesonide in experimental nickel–allergic contact dermatitis in individuals hypersensitive to budesonide. Br J Dermatol 145:38–44

    CAS  PubMed  Google Scholar 

  43. Luger T, Paul C (2007) Potential new indications of topical calcineurin inhibitors. Dermatology 215(suppl 1):45–54

    CAS  PubMed  Google Scholar 

  44. Queille-Roussel C, Graeber M, Thurston M et al (2000) SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm 42:349–350

    CAS  PubMed  Google Scholar 

  45. Mose KF et al (2018) Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone. Br J Clin Pharmacol 84(8):1719–1728

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Engel K, Reuter J, Seiler C et al (2008) Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. J Eur Acad Dermatol Venereol 22:447–450

    CAS  PubMed  Google Scholar 

  47. Grassberger M, Steinhoff M, Schneider D et al (2004) Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 13:721–730

    CAS  PubMed  Google Scholar 

  48. Schliemann S, Kelterer D, Bauer A et al (2008) Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Derm 58:299–306

    CAS  PubMed  Google Scholar 

  49. Han JS et al (2014) Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach. Int J Dermatol 53(10):e470–e471

    CAS  PubMed  Google Scholar 

  50. Thelmo MC, Lang W, Brooke E et al (2003) An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat 14:136–140

    CAS  PubMed  Google Scholar 

  51. Katsarou A et al (2012) Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol 22(2):192–196

    CAS  PubMed  Google Scholar 

  52. Belsito DV, Fowler JF Jr, Marks JG Jr et al (2004) Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 73:31–38

    PubMed  Google Scholar 

  53. Wong LS et al (2018) TRPA1 channel participates in tacrolimus-induced pruritus in a chronic contact hypersensitivity murine model. J Dermatol Sci 89(2):207–209

    CAS  PubMed  Google Scholar 

  54. Pereira U et al (2010) Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol 163(1):70–77

    CAS  PubMed  Google Scholar 

  55. Ring J, Barker J, Behrendt H et al (2005) Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European dermatology forum. J Eur Acad Dermatol Venereol 19:663–671

    CAS  PubMed  Google Scholar 

  56. Ohtsuki M, Morimoto H, Nakagawa H (2018) Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol 45(8):936–942

    PubMed  PubMed Central  Google Scholar 

  57. Chia BK, Tey HL (2015) Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 26(3):122–132

    CAS  PubMed  Google Scholar 

  58. (EPAR), E.p.a.r. Protopic: EPAR - Product Information, Annex I - Summary of product characteristics. 23.02.2020; Last updated 03.09.2018. Available from: https://www.ema.europa.eu/en/documents/product-information/protopic-epar-product-information_en.pdf

  59. Bollag W, Ott F (1999) Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology 199:308–312

    CAS  PubMed  Google Scholar 

  60. Cheng C, Michaels J, Scheinfeld N (2008) Alitretinoin: a comprehensive review. Expert Opin Investig Drugs 17:437–443

    CAS  PubMed  Google Scholar 

  61. Ruzicka T, Lynde CW, Jemec GB et al (2008) Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 158:808–817

    CAS  PubMed  Google Scholar 

  62. Blair HA, Scott LJ (2016) Alitretinoin: a review in severe chronic hand eczema. Drugs 76(13):1271–1279

    PubMed  Google Scholar 

  63. Ingram JR, Batchelor JM, Williams H (2009) Alitretinoin as a potential advance in the management of severe chronic hand eczema. Arch Dermatol 145:314–315

    PubMed  Google Scholar 

  64. Reymann F (1982) Two years’ experience with tigason treatment of pustulosis palmo-plantaris and eczema keratoticum manuum. Dermatologica 164:209–216

    CAS  PubMed  Google Scholar 

  65. Hanifin JM, Stevens V, Sheth P et al (2004) Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 150:545–553

    CAS  PubMed  Google Scholar 

  66. Thestrup-Pedersen K, Andersen KE, Menne T et al (2001) Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol 81:353–355

    CAS  PubMed  Google Scholar 

  67. Politiek K et al (2016) Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther 29(5):364–371

    PubMed  Google Scholar 

  68. Tan J et al (2015) Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. J Dermatolog Treat 26(4):373–375

    CAS  PubMed  Google Scholar 

  69. Song M et al (2017) Acitretin as a therapeutic option for chronic hand eczema. Ann Dermatol 29(3):385–387

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Brasch J, Becker D, Aberer W et al (2007) Contact dermatitis. J Dtsch Dermatol Ges 5:943–951

    PubMed  Google Scholar 

  71. Berneburg M, et al S1-Leitlinie zur UV-Phototherapie und Photochemotherapie. 2015 08/2015 23.02.2020]; Available from: https://www.awmf.org/uploads/tx_szleitlinien/013-029l_S1_UV-Phototherapie__Photochemotherapie_2015-08.pdf

  72. Schempp CM, Muller H, Czech W et al (1997) Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol 36:733–737

    CAS  PubMed  Google Scholar 

  73. Behrens S, von Kobyletzki G, Gruss C et al (1999) PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Photodermatol Photoimmunol Photomed 15:47–51

    CAS  PubMed  Google Scholar 

  74. Polderman MC, Govaert JC, le Cessie S et al (2003) A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 28:584–587

    CAS  PubMed  Google Scholar 

  75. Petering H, Breuer C, Herbst R et al (2004) Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 50:68–72

    PubMed  Google Scholar 

  76. Schmidt T, Abeck D, Boeck K et al (1998) UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol 78:318–319

    CAS  PubMed  Google Scholar 

  77. Krutmann J, Medve-Koenigs K, Ruzicka T et al (2005) Ultraviolet-free phototherapy. Photodermatol Photoimmunol Photomed 21:59–61

    PubMed  Google Scholar 

  78. Stege H (2008) Ultraviolet therapy in patients with chronic hand eczema. Hautarzt 59:696–702

    CAS  PubMed  Google Scholar 

  79. van Coevorden AM, Kamphof WG, van Sonderen E et al (2004) Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. Arch Dermatol 140:1463–1466

    PubMed  Google Scholar 

  80. Bayerl C, Gabea A, Peiler D et al (1999) Pilotstudie zur therapie des beruflich bedingten handekzems mit einer neuen tragbaren UVB-bestralungseinheit. Aktuelle Derm 25:302–305

    Google Scholar 

  81. Fairris GM, Jones DH, Mack DP et al (1984) Superficial X-ray therapy in the treatment of constitutional eczema of the feet. Br J Dermatol 111:500–502

    CAS  PubMed  Google Scholar 

  82. NICE (2007) Grenz rays therapy for inflammatory skin conditions. Retrieved 03 September 2009 from http://guidance.nice.org.uk/IPG236 and attachments http://guidance.nice.org.uk/IPG236/Guidance/pdf/English and http://www.nice.org.uk/guidance/index.jsp?action=download&o=31797

  83. Warner JA, Cruz PD Jr (2008) Grenz ray therapy in the new millennium: still a valid treatment option? Dermatitis 19:73–80

    PubMed  Google Scholar 

  84. Fairris GM, Jones DH, Mack DP et al (1985) Conventional superficial X-ray versus Grenz ray therapy in the treatment of constitutional eczema of the hands. Br J Dermatol 112:339–341

    CAS  PubMed  Google Scholar 

  85. Fenton L, Dawe RS (2016) Six years' experience of grenz ray therapy for the treatment of inflammatory skin conditions. Clin Exp Dermatol 41(8):864–870

    CAS  PubMed  Google Scholar 

  86. Granlund H, Erkko P, Eriksson E et al (1996) Comparison of cyclosporine and topical betamethasone-17, 21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 76:371–376

    CAS  PubMed  Google Scholar 

  87. Reitamo S, Granlund H (1994) Cyclosporin A in the treatment of chronic dermatitis of the hands. Br J Dermatol 130:75–78

    CAS  PubMed  Google Scholar 

  88. Werfel T et al (2016) S2k guideline on diagnosis and treatment of atopic dermatitis–short version. J Dtsch Dermatol Ges 14(1):92–106

    PubMed  Google Scholar 

  89. Schmitt J, Schmitt N, Meurer M (2007) Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 21:606–619

    CAS  PubMed  Google Scholar 

  90. Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358:1042–1045

    CAS  PubMed  Google Scholar 

  91. Vakeva L, Reitamo S, Pukkala E et al (2008) Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol 88:117–120

    CAS  PubMed  Google Scholar 

  92. Verma KK, Mahesh R, Srivastava P et al (2008) Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol 74:453–457

    PubMed  Google Scholar 

  93. Verma KK, Bansal A, Sethuraman G (2006) Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol 72:24–27

    PubMed  Google Scholar 

  94. Murphy GM, Maurice PD, Norris PG et al (1989) Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 121:639–646

    CAS  PubMed  Google Scholar 

  95. Anstey AV, Wakelin S, Reynolds NJ (2004) Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151:1123–1132

    CAS  PubMed  Google Scholar 

  96. Wise M, Callen JP (2007) Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 20:206–215

    PubMed  Google Scholar 

  97. Egan CA, Rallis TM, Meadows KP et al (1999) Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 40:612–614

    CAS  PubMed  Google Scholar 

  98. Shaffrali FC, Colver GB, Messenger AG et al (2003) Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 48:417–419

    PubMed  Google Scholar 

  99. Pickenacker A, Luger TA, Schwarz T (1998) Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 134:378–379

    CAS  PubMed  Google Scholar 

  100. Gooderham MJ et al (2018) Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 78(3 Suppl 1):S28–s36

    CAS  PubMed  Google Scholar 

  101. Moyle M et al (2019) Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol 28(7):756–768

    PubMed  PubMed Central  Google Scholar 

  102. Shirley M (2017) Dupilumab: first global approval. Drugs 77(10):1115–1121

    CAS  PubMed  Google Scholar 

  103. Oosterhaven JAF et al (2019) Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol 46(8):680–685

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Chipalkatti N et al (2018) Dupilumab as a treatment for allergic contact dermatitis. Dermatitis 29(6):347–348

    CAS  PubMed  Google Scholar 

  105. Crepy M-N, Nosbaum A, Bensefa-Colas L (2019) Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Contact Dermatitis 81(2):145–147

    PubMed  Google Scholar 

  106. Goldminz AM, Scheinman PL (2018) A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther 31(6):e12701–e12701

    PubMed  Google Scholar 

  107. Joshi SR, Khan DA (2018) Effective use of Dupilumab in managing systemic allergic contact dermatitis. Dermatitis 29(5):282–284

    CAS  PubMed  Google Scholar 

  108. Machler BC et al (2019) Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol 80(1):280–281.e1

    PubMed  Google Scholar 

  109. Raffi J et al (2020) The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol 82(1):132–138

    CAS  PubMed  Google Scholar 

  110. Stout M, Silverberg JI (2019) Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol 81(1):157–162

    CAS  PubMed  Google Scholar 

  111. He H, Guttman-Yassky E (2019) JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol 20(2):181–192

    PubMed  Google Scholar 

  112. Worm M, et al (2019) Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol

    Google Scholar 

  113. Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736–744

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Bagot M, Terki N, Bacha S et al (1999) Per os desensitization in nickel contact eczema: a double-blind placebo-controlled clinico-biological study. Ann Dermatol Venereol 126:502–504

    CAS  PubMed  Google Scholar 

  115. Bonamonte D et al (2011) Efficacy of oral hyposensitization in allergic contact dermatitis caused by nickel. Contact Dermatitis 65(5):293–301

    CAS  PubMed  Google Scholar 

  116. Handa S, Sahoo B, Sharma VK (2001) Oral hyposensitization in patients with contact dermatitis from Parthenium hysterophorus. Contact Derm 44:279–282

    CAS  PubMed  Google Scholar 

  117. Elias PM (2008) Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis. Drug Discov Today Dis Mech 5:e33–e38

    PubMed  PubMed Central  Google Scholar 

  118. Denda M (2002) New strategies to improve skin barrier homeostasis. Adv Drug Deliv Rev 54(suppl 1):S123–S130

    CAS  PubMed  Google Scholar 

  119. Lee JY, Effendy I, Maibach HI (1997) Acute irritant contact dermatitis: recovery time in man. Contact Derm 36:285–290

    CAS  PubMed  Google Scholar 

  120. Gloor M, Senger B, Langenauer M et al (2004) On the course of the irritant reaction after irritation with sodium lauryl sulphate. Skin Res Technol 10:144–148

    PubMed  Google Scholar 

  121. Choi JM, Lee JY, Cho BK (2000) Chronic irritant contact dermatitis: recovery time in man. Contact Derm 42:264–269

    CAS  PubMed  Google Scholar 

  122. Wilhelm K-P, Freitag G, Wolff HH (1994) Surfactant-induced skin irritation and skin repair: evaluation of a cumulative human irritation model by noninvasive techniques. J Am Acad Dermatol 31:981–987

    CAS  PubMed  Google Scholar 

  123. Leskur D et al (2019) Anatomical site differences of sodium laurylsulphate induced irritation: randomised controlled trial. Br J Dermatol 181(1):19–20

    Google Scholar 

  124. Fluhr JW, Kuss O, Diepgen T et al (2001) Testing for irritation with a multifactorial approach: comparison of eight non-invasive measuring techniques on five different irritation types. Br J Dermatol 145:696–703

    CAS  PubMed  Google Scholar 

  125. Freeman S, Maibach H (1988) Study of irritant contact dermatitis produced by repeat patch test with sodium lauryl sulfate and assessed by visual methods, transepidermal water loss, and laser Doppler velocimetry. J Am Acad Dermatol 19:496–502

    CAS  PubMed  Google Scholar 

  126. Widmer J, Elsner P, Burg G (1994) Skin irritant reactivity following experimental cumulative irritant contact dermatitis. Contact Derm 30:35–39

    CAS  PubMed  Google Scholar 

  127. Zhai H, Chang YC, Singh M et al (1999) In vivo nickel allergic contact dermatitis: human model for topical therapeutics. Contact Derm 40:205–208

    CAS  PubMed  Google Scholar 

  128. Hindsen M, Bruze M, Christensen OB (1997) The significance of previous allergic contact dermatitis for elicitation of delayed hypersensitivity to nickel. Contact Derm 37:101–106

    CAS  PubMed  Google Scholar 

  129. Allenby CF, Basketter DA (1993) An arm immersion model of compromised skin (II). Influence on minimal eliciting patch test concentrations of nickel. Contact Derm 28:129–133

    CAS  PubMed  Google Scholar 

  130. Pedersen L, Johansen JD, Held E et al (2004) Augmentation of skin response by exposure to a combination of allergens and irritants – a review. Contact Derm 50:265–273

    CAS  PubMed  Google Scholar 

  131. Skudlik C, Weisshaar E, Scheidt R et al (2009) Multicenter study “medical-occupational rehabilitation procedure skin – optimizing and quality assurance of inpatient-management (ROQ)”. J Dtsch Dermatol Ges 7:122–126

    PubMed  Google Scholar 

  132. Held E, Sveinsdottir S, Agner T (1999) Effect of long-term use of moisturizer on skin hydration, barrier function and susceptibility to irritants. Acta Derm Venereol 79:49–51

    CAS  PubMed  Google Scholar 

  133. Goh CL (1991) Cutting oil dermatitis on Guinea pig skin (I). Cutting oil dermatitis and barrier cream. Contact Derm 24:16–21

    CAS  PubMed  Google Scholar 

  134. Buraczewska I, Berne B, Lindberg M et al (2007) Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol 156:492–498

    CAS  PubMed  Google Scholar 

  135. Hachem JP, De Paepe K, Vanpee E et al (2002) The effect of two moisturisers on skin barrier damage in allergic contact dermatitis. Eur J Dermatol 12:136–138

    PubMed  Google Scholar 

  136. Zachariae C, Held E, Johansen JD et al (2003) Effect of a moisturizer on skin susceptibility to NiCl2. Acta Derm Venereol 83:93–97

    CAS  PubMed  Google Scholar 

  137. Proksch E, Brandner JM, Jensen JM (2008) The skin: an indispensable barrier. Exp Dermatol 17:1063–1072

    PubMed  Google Scholar 

  138. Feingold KR (1991) The regulation of epidermal lipid synthesis by permeability barrier requirements. Crit Rev Ther Drug Carrier Syst 8:193–210

    CAS  PubMed  Google Scholar 

  139. Grubauer G, Elias PM, Feingold KR (1989) Transepidermal water loss: the signal for recovery of barrier structure and function. J Lipid Res 30:323–333

    CAS  PubMed  Google Scholar 

  140. Zhai H, Maibach HI (2002) Occlusion vs. skin barrier function. Skin Res Technol 8:1–6

    PubMed  Google Scholar 

  141. Buraczewska I, Berne B, Lindberg M et al (2009) Moisturizers change the mRNA expression of enzymes synthesizing skin barrier lipids. Arch Dermatol Res 301(8):587–594

    CAS  PubMed  Google Scholar 

  142. Jungersted JM, Hellgren LI, Jemec GB et al (2008) Lipids and skin barrier function–a clinical perspective. Contact Derm 58:255–262

    CAS  PubMed  Google Scholar 

  143. Goldstein AM, Abramovits W (2003) Ceramides and the stratum corneum: structure, function, and new methods to promote repair. Int J Dermatol 42:256–259

    CAS  PubMed  Google Scholar 

  144. Feingold KR (2007) Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res 48:2531–2546

    CAS  PubMed  Google Scholar 

  145. Elias PM (2006) Improving barrier function. In: Elias PM, Feingold KR (eds) Skin barrier. Taylor & Francis, New York

    Google Scholar 

  146. Kucharekova M, van De Kerkhof PC, van Der Valk PG (2003) A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based emollient as adjunct in the treatment of chronic hand dermatitis. Contact Derm 48:293–299

    CAS  PubMed  Google Scholar 

  147. Denda M (2009) Methodology to improve epidermal barrier homeostasis: how to accelerate the barrier recovery? Int J Cosmet Sci 31:79–86

    CAS  PubMed  Google Scholar 

  148. Fluhr JW, Darlenski R, Surber C (2008) Glycerol and the skin: holistic approach to its origin and functions. Br J Dermatol 159:23–34

    CAS  PubMed  Google Scholar 

  149. Barany E, Lindberg M, Loden M (2000) Unexpected skin barrier influence from nonionic emulsifiers. Int J Pharm 195:189–195

    CAS  PubMed  Google Scholar 

  150. Hachem JP, Behne M, Aronchik I et al (2005) Extracellular pH controls NHE1 expression in epidermis and keratinocytes: implications for barrier repair. J Invest Dermatol 125:790–797

    CAS  PubMed  Google Scholar 

  151. Mauro T, Holleran WM, Grayson S et al (1998) Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res 290:215–222

    CAS  PubMed  Google Scholar 

  152. Kim E, Kim S, Nam GW et al (2009) The alkaline pH-adapted skin barrier is disrupted severely by SLS-induced irritation. Int J Cosmet Sci 31(4):263–269

    CAS  PubMed  Google Scholar 

  153. Buraczewska I, Loden M (2005) Treatment of surfactant-damaged skin in humans with creams of different pH values. Pharmacology 73:1–7

    CAS  PubMed  Google Scholar 

  154. Ong PY (2009) Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 14:165–179

    CAS  PubMed  Google Scholar 

  155. Watkins SA, Maibach H (2009) The hardening phenomenon in irritant contact dermatitis: an interpretative update. Contact Derm 60:123–130

    PubMed  Google Scholar 

  156. Schoepe S, Schacke H, May E et al (2006) Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15:406–420

    CAS  PubMed  Google Scholar 

  157. Kao JS, Fluhr JW, Man MQ et al (2003) Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 120:456–464

    CAS  PubMed  Google Scholar 

  158. Kolbe L, Kligman AM, Schreiner V et al (2001) Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 7:73–77

    CAS  PubMed  Google Scholar 

  159. Jensen JM, Pfeiffer S, Witt M et al (2009) Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 123:1124–1133

    CAS  PubMed  Google Scholar 

  160. Farage MA, Miller KW, Elsner P et al (2007) Structural characteristics of the aging skin: a review. Cutan Ocul Toxicol 26:343–357

    PubMed  Google Scholar 

  161. Lim SH, Kim SM, Lee YW et al (2008) Change of biophysical properties of the skin caused by ultraviolet radiation-induced photodamage in Koreans. Skin Res Technol 14:93–102

    CAS  PubMed  Google Scholar 

  162. Holleran WM, Uchida Y, Halkier-Sorensen L et al (1997) Structural and biochemical basis for the UVB-induced alterations in epidermal barrier function. Photodermatol Photoimmunol Photomed 13:117–128

    CAS  PubMed  Google Scholar 

  163. Löffler H, Aramaki J, Friebe K et al (2002) Changes in skin physiology during bath PUVA therapy. Br J Dermatol 147:105–109

    PubMed  Google Scholar 

  164. Lehmann P, Holzle E, Melnik B et al (1991) Effects of ultraviolet A and B on the skin barrier: a functional, electron microscopic and lipid biochemical study. Photodermatol Photoimmunol Photomed 8:129–134

    CAS  PubMed  Google Scholar 

  165. Haratake A, Uchida Y, Mimura K et al (1997) Intrinsically aged epidermis displays diminished UVB-induced alterations in barrier function associated with decreased proliferation. J Investig Dermatol 108:319–323

    CAS  PubMed  Google Scholar 

  166. Bissett DL, Hannon DP, Orr TV (1987) An animal model of solar-aged skin: histological, physical, and visible changes in UV-irradiated hairless mouse skin. Photochem Photobiol 46:367–378

    CAS  PubMed  Google Scholar 

  167. Elias PM (1986) Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 15:797–809

    CAS  PubMed  Google Scholar 

  168. Schindler M et al (2014) Immunomodulation in patients with chronic hand eczema treated with oral alitretinoin. Int Arch Allergy Immunol 165(1):18–26

    CAS  PubMed  Google Scholar 

  169. Tagami H, Tadaki T, Obata M et al (1992) Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in Guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol 127:470–475

    CAS  PubMed  Google Scholar 

  170. Fluhr JW, Vienne MP, Lauze C et al (1999) Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology 199(suppl 1):57–60

    CAS  PubMed  Google Scholar 

  171. Jungersted JM et al (2010) Changes in skin barrier during treatment with systemic alitretinoin: focus on skin susceptibility and stratum corneum ceramides. Arch Dermatol Res 302(9):653–656

    CAS  PubMed  Google Scholar 

  172. Jacobson MK, Kim H, Coyle WR et al (2007) Effect of myristyl nicotinate on retinoic acid therapy for facial photodamage. Exp Dermatol 16:927–935

    CAS  PubMed  Google Scholar 

  173. Draelos ZD, Ertel KD, Berge CA (2006) Facilitating facial retinization through barrier improvement. Cutis 78:275–281

    PubMed  Google Scholar 

  174. Stucker M, Hoffmann M, Altmeyer P (2002) Instrumental evaluation of retinoid-induced skin irritation. Skin Res Technol 8:133–140

    CAS  PubMed  Google Scholar 

  175. Berndt U, Hinnen U, Iliev D et al (2000) Hand eczema in metalworker trainees–an analysis of risk factors. Contact Derm 43:327–332

    CAS  PubMed  Google Scholar 

  176. Tsutsumi M, Denda M (2007) Paradoxical effects of beta-estradiol on epidermal permeability barrier homeostasis. Br J Dermatol 157:776–779

    CAS  PubMed  Google Scholar 

  177. Gunathilake R, Schurer NY, Shoo BA et al (2009) PH-regulated mechanisms account for pigment-type differences in epidermal barrier function. J Invest Dermatol 129:1719–1729

    CAS  PubMed  PubMed Central  Google Scholar 

  178. Kowatzki D, Macholdt C, Krull K et al (2008) Effect of regular sauna on epidermal barrier function and stratum corneum water-holding capacity in vivo in humans: a controlled study. Dermatology 217:173–180

    CAS  PubMed  Google Scholar 

  179. Watson AL, Fray TR, Bailey J et al (2006) Dietary constituents are able to play a beneficial role in canine epidermal barrier function. Exp Dermatol 15:74–81

    CAS  PubMed  Google Scholar 

  180. Williams S, Krueger N, Davids M et al (2007) Effect of fluid intake on skin physiology: distinct differences between drinking mineral water and tap water. Int J Cosmet Sci 29:131–138

    CAS  PubMed  Google Scholar 

  181. Brand RM, Jendrzejewski JL, Charron AR (2007) Potential mechanisms by which a single drink of alcohol can increase transdermal absorption of topically applied chemicals. Toxicology 235:141–149

    CAS  PubMed  Google Scholar 

  182. Robles TF (2007) Stress, social support, and delayed skin barrier recovery. Psychosom Med 69:807–815

    PubMed  Google Scholar 

  183. Denda M, Tsuchiya T (2000) Barrier recovery rate varies time-dependently in human skin. Br J Dermatol 142:881–884

    CAS  PubMed  Google Scholar 

  184. Rogers J, Harding C, Mayo A et al (1996) Stratum corneum lipids: the effect of ageing and the seasons. Arch Dermatol Res 288:765–770

    CAS  PubMed  Google Scholar 

  185. Grether-Beck S, Muhlberg K, Brenden H et al (2008) Bioactive molecules from the blue lagoon: in vitro and in vivo assessment of silica mud and microalgae extracts for their effects on skin barrier function and prevention of skin ageing. Exp Dermatol 17:771–779

    PubMed  Google Scholar 

  186. Proksch E, Nissen HP, Bremgartner M et al (2005) Bathing in a magnesium-rich dead sea salt solution improves skin barrier function, enhances skin hydration, and reduces inflammation in atopic dry skin. Int J Dermatol 44:151–157

    PubMed  Google Scholar 

  187. Diepgen TL et al (2015) Guidelines for diagnosis, prevention and treatment of hand eczema–short version. Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol: JDDG 13(1):77–85

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital Jena, Jena, Germany

    Laine Ludriksone, Dimitar Antonov, Sibylle Schliemann & Peter Elsner

  2. Klinik für Hautkrankheiten und Allergologie, Heinrich-Braun-Klinikum gemeinnützige GmbH, Zwickau, Germany

    Dimitar Antonov

Authors
  1. Laine Ludriksone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitar Antonov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sibylle Schliemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Elsner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laine Ludriksone .

Editor information

Editors and Affiliations

  1. Amtssygehuset Gentofte Dept. Dermatology, Hellerup, Denmark

    Jeanne Duus Johansen

  2. Federal Institute for Vaccines & Biomed, Paul Ehrlich Institut Federal Institute for Vaccines & Biomed, Langen, Bayern, Germany

    Vera Mahler

  3. Institut le Bel Labo. Dermatochimie, Strasbourg CX, France

    Jean-Pierre Lepoittevin

  4. Hautklinik, Städtische Kliniken Dortmund Klinikzentrum Mitte, Dortmund, Germany

    Peter J. Frosch

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ludriksone, L., Antonov, D., Schliemann, S., Elsner, P. (2020). Therapy of Allergic and Irritant Contact Dermatitis. In: Johansen, J., Mahler, V., Lepoittevin, JP., Frosch, P. (eds) Contact Dermatitis. Springer, Cham. https://doi.org/10.1007/978-3-319-72451-5_72-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72451-5_72-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72451-5

  • Online ISBN: 978-3-319-72451-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation